MedTrace Logo

Phase II Study of T-DX in HER2-positive Breast Cancer Brain Metastases

NCT04752059 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2023-05-12

No results posted yet for this study

Summary

Trastuzumab-Deruxtecan (T-DXd; DS-8201a) in HER2-positive Breast Cancer Patients with newly diagnosed or progressing Brain Metastases

Conditions

  • Breast Cancer Stage IV

Interventions

DRUG

Trastuzumab deruxtecan

Trastuzumab-deruxtecan 5.4 mg/kg body weight i.v. on day 1 once every three weeks until progression or death

Sponsors & Collaborators

  • Daiichi Sankyo

    collaborator INDUSTRY

  • Medical University of Vienna

    lead OTHER

Principal Investigators

  • Rupert Bartsch, MD · Medical University of Vienna

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-28
Primary Completion
2023-05-01
Completion
2023-05-01

Countries

  • Austria

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04752059 on ClinicalTrials.gov